A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles
✍ Scribed by Yamei Niu; Nobukazu Komatsu; Yoshihiro Komohara; Satoko Matsueda; Shigeru Yutani; Yuki Ishihara; Minoru Itou; Akira Yamada; Kyogo Itoh; Shigeki Shichijo
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 301 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
C35‐44 peptide is a well known HLA‐A2‐restricted CTL epitope originating from hepatitis C virus (HCV) core protein. It was reported that the majority of HCV positive patients had significant levels of serum IgG specific to this peptide. This study addressed whether C35‐44 peptide could induce CTL activity restricted to various HLA class IA alleles or could not. This peptide demonstrated binding activity to HLA‐A*2402, ‐A*2601, ‐A*3101, and ‐A*3303 molecules, but not to HLA‐A*1101 by means of stabilization assay. This peptide also induced CTL activity restricted to each of them, except HLA‐A11^+^ peripheral blood mononuclear cells from HCV 1b^+^ patients by means of ^51^Cr‐release assay. With regard to HLA‐A2 subtypes, this peptide demonstrated binding activity to HLA‐A*0201 and ‐A*0206, but not to ‐A*0207 molecules. Furthermore, this peptide induced CTL activity from both the patients and healthy donors with all the HLA class IA molecules mentioned above by means of interferon‐γ production assay. These results may provide new insights for the development of a novel peptide vaccine against HCV compatible with various HLA class IA types. J. Med. Virol. 81:1232–1240, 2009. © 2009 Wiley‐Liss, Inc.